Advertisement
Advertisement
U.S. Markets close in 4 hrs 25 mins
Advertisement
Advertisement
Advertisement
Advertisement

Agios Pharmaceuticals, Inc. (AGIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
23.12+0.95 (+4.29%)
As of 11:34AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close22.17
Open22.17
Bid23.16 x 800
Ask23.20 x 800
Day's Range21.94 - 23.29
52 Week Range16.75 - 58.61
Volume90,242
Avg. Volume720,955
Market Cap1.256B
Beta (5Y Monthly)1.44
PE Ratio (TTM)0.93
EPS (TTM)24.95
Earnings DateApr 27, 2022 - May 02, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est38.80
  • GlobeNewswire

    CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease

    Working together on the world’s first treatment that targets the underlying causes of pyruvate kinase (“PK”) deficiency in children under the age of 18Expanded collaboration to include Phase 3 ACTIVATE-kids and ACTIVATE-kidsT studies CENTOGENE’s genetic testing and Biodatabank identify causative mutations, including the UGT1A1 and PKLR genes, and supports precise diagnosis CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 13, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the comme

  • GlobeNewswire

    Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress

    – Treatment with PYRUKYND® Associated with Early and Robust Hemoglobin Responses in Phase 3 ACTIVATE and Extension Studies; Approximately One-Third of Patients Achieved Normal Hemoglobin Levels at Least Once – – PYRUKYND®-Treated Patients Reported Significant Improvements in PK Deficiency Signs, Symptoms and Impacts, with Greater Improvements Evident in Hemoglobin Responders – – New Analysis from Peak Registry Demonstrates Wide Range of Comorbidities and Complications in PK Deficiency Patients R

  • Benzinga

    Agios Is Looking For Development Partner, Lays Off Exploratory Research Staff

    Agios Pharmaceuticals Inc (NASDAQ: AGIO) will be letting go of 50 employees and shuffling its R&D leadership team to focus internal research efforts on its lead programs. Chief Medical Officer Sarah Gheuens will assume the role of R&D and Chief Scientific Officer at the end of July. Agios' chief scientific officer, Bruce Car, will step down from the role and remain with the company through July to facilitate the transition. The changes will unlock about $40 million to $50 million in cost savings

Advertisement
Advertisement